13052-92-1Relevant articles and documents
Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold
Yin, Siyuan,Tang, Chunming,Wang, Bin,Zhang, Ying,Zhou, Liliang,Xue, Lingjing,Zhang, Can
, p. 26 - 36 (2016)
For the purpose of developing novel EGFR/HER2 tyrosine kinases inhibitors with high inhibition activity and low toxicity, two novel series of oxazolo[4,5-g]quinazolin-2(1H)-one derivatives as EGFR/HER2 dual inhibitors introducing two electrophiles 2-(2-bromoacetyl)ethyl and 2-(2-chloroacetoxy)ethyl group as side-chain at 1-position respectively and evaluated their EGFR and HER2 inhibition activity and toxicity comparing with Lapatinib. All these compounds were evaluated by EGFR and HER2 kinase inhibition and two anti-proliferation assays in vitro. Most of the designed compounds exhibited moderate to high inhibition activity against EGFR and HER2. Especially, compounds 11o, 11p, 12e and 12f presented high inhibition against EGFR and HER2. Furthermore, compounds 11p and 12f also had well exhibition to excellent anti-proliferation activity against human lung adenocarcinoma cell line (A549) and human breast cancer cell line (SK-Br3), and 12f also exhibited the lowest toxicity against human embryonic lung fibroblast cell line (HELF) cell. Finally, compound 12f presented remarkably higher inhibition efficacy towards tumour growth than Lapatinib in a mouse lewis lung cancer (LLC) xenograft model.
Synthetic method for derivatives of nocarbenzoxazoles and pharmaceutical composition containing the derivatives of nocarbenzoxazoles
-
Paragraph 0032; 0038, (2019/10/22)
An object of the present invention is to provide an anti-inflammation agent having excellent efficacy and minimized side effects by solving side effects of conventional anti-inflammation agents, and to provide a synthesis method thereof. By using a POCl_3-mediated ring dehydration reaction using commercially available inexpensive raw materials and selective and/or complete demethylation and a reduction reaction as main reactions, nocabenzoxazole derivatives are easily synthesized in a 15 to 49% yield and it is confirmed by testing anti-inflammatory activity of compounds.COPYRIGHT KIPO 2019
Synthetic method for nocarbenzoxazole G and derivatives of nocarbenzoxaoles
-
Paragraph 0036; 0042, (2019/12/25)
An object of the present invention is to provide an anti-inflammation agent having excellent efficacy and minimized side effects by solving side effects of existing anti-inflammation agents, and to provide a novel nocarbenzoxazole derivative and a synthesis method thereof. By using a POCl_3-mediated ring dehydration reaction using commercially available inexpensive raw materials and selective and/or complete demethylation and a reduction reaction as main reactions, nocarbenzoxazole G and nocarbenzoxazole derivatives are easily synthesized in a 15 to 49% of yield and it is confirmed by testing anti-inflammatory activity of compounds.COPYRIGHT KIPO 2020
A facile hybrid 'flow and batch' access to substituted 3,4-dihydro-2: H -benzo [b] [1,4]oxazinones
Lin, Andrew J. S.,Russell, Cecilia C.,Baker, Jennifer R.,Frailey, Shelby L.,Sakoff, Jennette A.,McCluskey, Adam
supporting information, p. 8732 - 8742 (2016/10/03)
We describe a simple flow chemistry approach to libraries of ethyl 3-oxo-2-(substituted-phenylamino)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylates (12a-l) and N-ethyl-3-oxo-2-(substituted-phenylamino)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamides (13a-l) in 38-87% yields. This scaffold is poorly described in the chemical literature. Screening against a panel of 11 cancer and one normal cell line showed that the amide linked library 13a-l was devoid of toxicity. Whereas the ester linked analogues 12b, 12c, 12g, 12j and 12l were highly cytotoxic with growth inhibition (GI50) values from 0.34 to >50 μM across all cell lines, with the 2-OH-Ph substituted 12l analogue presenting with sub-micromolar potency against the A2780 (ovarian; 0.34 ± 0.04 μM), BEC-2 (glioblastoma; 0.35 ± 0.06 μM), MIA (pancreas; 0.91 ± 0.054 μM) and SMA (murine glioblastoma; 0.77 ± 0.029 μM) carcinoma cell lines. Interestingly, the U87 glioblastoma cell line showed inherent resistance to growth inhibition by all analogues (GI50 32 to >50 μM) while the A2780 cells were highly sensitive (GI50 3.8-0.34 μM), suggesting that the analogues developed herein may be valuable lead compounds for the development of ovarian carcinoma specific cytotoxic agents. The differences in amide versus ester cytotoxicity was consitent with esterase cleaveage to release the cytotoxic warhead.
